Heidi has served as the Chief Financial Officer of Pardes Biosciences, Inc. since January 2021 and was an advisor to Pardes from April 2020 until January 2021. She has over 25 years of financial operations experience with both public and private companies. Prior to joining Pardes, Heidi was Chief Financial Officer of Imbria Pharmaceuticals, Inc. from April 2019 to July 2020 and Chief Financial Officer of Respivant Sciences from November 2018 to April 2019. From August 2014 to July 2018, Heidi served as Chief Financial Officer and Secretary of Kura Oncology. Heidi also served as Chief Financial Officer of Wellspring Biosciences, Inc., a privately held biopharmaceutical company, and its parent company Araxes Pharma LLC, from July 2012 to July 2018 and served as Secretary of Wellspring and Araxes from July 2012 to January 2015. Heidi previously served as an independent financial consultant for several years assisting with various start-up activities for early-stage companies, SEC reporting and Sarbanes-Oxley implementation and compliance.